Ligand id: 7673

Name: lesinurad

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 93.31
Molecular weight 403
XLogP 6.16
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Following the completion of successful Phase III clinical trials, the US FDA approved lesinurad as a treatment for the hyperuricaemia which causes the symptoms of gout in December 2015. The EMA followed with approval in April 2016.
Click here to view ClinicalTrials.gov's list of current lesinurad trials.
A fixed dose combination of lesinuradl and the xanthine dehydrogenase inhibitor allopurinol (Duzallo®) was FDA approved in August 2017, for the treatment of gout that is not controlled by allopurinol alone.
Mechanism Of Action and Pharmacodynamic Effects
Lesinurad inhibits the uric acid transporter URAT1 which is expressed in the proximal tubule of the kidney. This reduces re-absorption of uric acid, thereby promoting its renal excretion.
External links